Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

medRxiv logoLink to medRxiv
[Preprint]. 2025 Aug 18:2025.03.12.25323875. Originally published 2025 Mar 13. [Version 3] doi: 10.1101/2025.03.12.25323875

Antimicrobial selection for resistance in four major pathogens in the US Veterans Affairs Healthcare System, 2007-2021

Thi Mui Pham, Yue Zhang, McKenna Nevers, Haojia Li, Karim Khader, Yonatan H Grad, Matthew Samore, Marc Lipsitch
PMCID: PMC11952605  PMID: 40162274

Abstract

Background

Systematic evidence on antimicrobial selection for antimicrobial resistance (AMR) is scarce. We estimated the effect of prescribing key antibiotic classes on AMR across U.S. Veterans Affairs Medical Centres (VAMC).

Methods

We analysed clinical isolates of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae , and Pseudomonas aeruginosa from 138 VAMC from Feb 1, 2007 to Dec 31, 2021. Antimicrobial prescribing was measured as inpatient days of therapy per 1000 patient-days; multidrug resistance as number of resistant phenotypes per 1,000 admissions. Temporal trends were modelled using generalized estimating equations and average annual percentage changes (AAPC). Multilevel multinomial logistic regression related facility-level antibiotic prescribing (days of therapy per 100 patient-days in the last 14d) to the relative odds of resistant phenotypes.

Findings

Hospital-onset infection incidence declined for all pathogens, except third-generation cephalosporin (3GC)-resistant E coli . Antimicrobial prescribing remained stable or decreased, except 3GC prescribing, which increased from 2007 until 2019 (AAPC=2·4%, 95% CI 1·3%–3·5%, p-value<0.0001). Fluoroquinolone (FQL) use was associated with resistance across all pathogens. In S aureus , each day of FQL treatment was linked to a 4·6% (95CI: 1·5, 7·7, p-value=0.0127) increase in the relative odds of isolating FQL-resistant, macrolide-susceptible, methicillin-resistant S aureus . Anti-staphylococcal beta-lactams were not linked to MRSA. Each day of 3GC treatment increased the odds of isolating 3GC- and beta-lactam/beta-lactamase-resistant E coli by 5·2% (95%CI: 1·3%, 9·4%, p-value=0.0079) and K pneumoniae by 3·0% (95% CI: −0·1%-6·2%, p-value=0.0600). Each day of carbapenem treatment increased the odds of carbapenem-resistant, FQL- and BL/BLI-susceptible P aeruginosa by 15·7% (95%CI: 9·4%, 22·4%, p-value<0.0001).

Interpretation

Higher facility-level antimicrobial use increased the odds of corresponding resistant phenotypes, with important exceptions. FQLs selected for resistance across multiple pathogens. Increased 3GC prescribing likely offset reductions in FQLs and was associated with co-resistance in E coli . These findings underscore the need for comprehensive stewardship that coordinates strategies across antimicrobials.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from medRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES